ExcerptRecent advances in the functional power of artificial intelligence (AI) have prompted an urgent warning from industry leaders and researchers concerning its “profound risks to society and humanity.”1 Their open letter is admirable not only for its succinct identification of said risks, which include the mass dissemination of misinformation, loss of jobs, and even the possible extinction of our species, but also for its clear normative framing of the problem: “Should we let machines flood our information channels with propaganda and (...) untruth? Should we automate away all the jobs, including the fulfilling ones? Should we develop nonhuman minds that might eventually outnumber, outsmart, obsolete and replace us? Should we risk loss of control of our civilization?”2. (shrink)

Occasionally you will hear it said that the violence perpetrated by organizations such as Al Qaeda is “nihilistic.” The senses of the term as thus employed seem to be largely intuitive, and involve a cluster of notions. The journalist and pundit Christopher Hitchens, for example, offers up such descriptions as “sinister grandiosity,” “pointless nastiness,” and “the tactic of demanding the impossible and demanding it at gun- point.”1 The idea is that contrary to the revolutionary, idealist rhetoric of those enacting the (...) violence, there is something hollow, cruel, and irratio- nal at the center of such actions. This intuitive application of the term “nihilistic” to organizations such as Al Qaeda has substantial merit, and it is in fact possible to specify a more detailed philosophical and psycholog- ical basis to the concept.2 A properly elaborated concept of nihilism is of considerable interpretive utility where some of the familiar socio-political concepts like “colonialism,” “globalization,” and the like have demon- strable shortcomings. Hegel and Nietzsche have, in separate ways, devel- oped the sort of philosophical and psychological basis to the notion of nihilism as discussed here. (shrink)

IntroductionThe COVID-19 pandemic has led to unprecedented strain to healthcare systems worldwide and posed unique challenges to the healthcare professionals and the general public.ObjectivesThe aim of this study is to evaluate the impact of COVID-19 on the mental health, behavioral, and physical wellbeing of HCPs in the early and mid-term periods of the pandemic in comparison to non-HCPs. Thus, facilitating and guiding optimum planning and delivery of support to HCPs.Methods and AnalysisAn observational cross-sectional survey and cohort study aiming to enroll (...) over 1050 participants. Study questionnaires will be completed at baseline and after 6-weeks and 4-months. Recruitment initiated July 2020. The study was designed in London, United Kingdom, but open to participants worldwide. Baseline: Questionnaires comprising of validated self-administered screening tools for depression, anxiety, sleep-related issues, wellbeing, and burnout. The questionnaires also explore changes in behavior and physical wellbeing of the participants. In addition, associations of these mental health and behavioral factors with work-related factors and support will be explored. Six-weeks and 4-months follow-up: Follow-up questionnaires will assess change in symptoms of anxiety and depression, sleep disorders, use of alcohol and other substances, behavioral or interpersonal relationship changes. Physical wellbeing will be assessed through the presence of suspected or confirmed COVID-19 infection and absence from work. We will also evaluate the impact of variable provision of personal protection equipment, extended working hours, and concern for the wellbeing of family members, anxiety levels, and evidence of burnout.Statistical ConsiderationsThe study has 80% power to detect a 10% difference of combined depression and/or anxiety symptoms between the groups using two-sided type 1 error at 0.05 at baseline. Assuming that only 50% of these HCPs agree to be a part of a cohort survey, we will have 80% power to detect around 12% difference in the two groups in reported physical symptoms, or prevalence of depression and/or anxiety at the end of the study.EthicsThe study was approved by the Cambridge East, Research Ethics Committee.Trial Registration NumberClinicalTrials.gov, NCT04433260. (shrink)